HomeStocksINDRAMEDCO

I

Indraprastha Medical Corporation

INDRAMEDCO Share Price

Healthcare Services
mtf MTF 2.00x

467.70

-0.05 (-0.01%)loss

as on 13 Aug 2025 at 15:57

1D
img
12
img
100% Buy
Bulb

Today Indraprastha Medical Corporation opened at 474.00 while its previous close was at 467.75. In todays trading session INDRAMEDCO reached a high of 474.00 and low of 464.00. The average traded price for today is 468.35. The 50 DMA stands at 320.04 and 200 DMA is at 289.54. Looking at intraday trend, the stock is moving sideways.

chartsarrowTradingViewarrow
TradingView Logo

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

INDRAMEDCO Stock Performance

Markets Today

High

474.00

Low

464.00

Open at

474.00

Prev Close

467.75

Volumes

1,23,948

Avg Price

468.35

Lower Circuit

374.20

Upper Circuit

561.20

Last Traded Details

Quantity

22

Time

15:57:18

Price Movement

464.00
467.70
474.00
Loss 0.80%down side
up side1.33% profit

Historical Performance

3 M High

523.90

3 M Low

387.00

1 Yr High

572.00

1 Yr Low

307.25

3 Yr High

572.00

3 Yr Low

60.45

5 Yr High

572.00

5 Yr Low

45.30

1-Year Performance

307.25
467.70
572.00
loss0.80%down side
up side1.33% profit

INDRAMEDCO Analyst Rating

Buy

Analysts have suggested that investors can Buy this Stock

- By Refinitiv from 1 analysts

Buy

100%

Hold

0%

Sell

0%


INDRAMEDCO News

View All News arrow

PTC India Financial Services Faces Rs 6.4 Lakh Penalty as Regional Director Dismisses Appeals

sentiment_img

PTC India Financial Services Ltd received orders from the Regional Director dismissing all three appeals against Show Cause Notices issued by the Registrar of Companies. The company must pay penalties totaling Rs 6.40 lakh for violations during FY 2021-22. The violations include failing to facilitate Independent Directors in seeking professional legal advice (Rs 70,000 penalty), delays in sharing documents with Independent Directors for legal opinion (Rs 70,000 penalty), and failure to maintain prescribed composition of the Nomination and Remuneration Committee (Rs 5 lakh penalty). The company states there is no material impact on operations except for the penalty amount, for which provisions have already been created in the books of accounts.

20 minutes ago

SPEL Semiconductor Announces Leadership Changes and Quarterly Results with Going Concern Qualification

sentiment_img

SPEL Semiconductor Limited's board approved several key decisions on August 13, 2025. The company appointed Dr. G. Nagarajan as Additional Director while Dr. Enakshi Bhattacharya resigned as Independent Director. The board also approved M/s. S Dhanapal & Associates LLP as Secretarial Auditors for 5 years and authorized the sale of open land in factory premises, both subject to shareholder approval. The company released unaudited financial results for the quarter ended June 30, 2025, which received a qualified review from auditors due to material uncertainty about the company's ability to continue as a going concern, citing losses and negative cash flows. The company operates in integrated circuit manufacturing and assembly, with losses attributed mainly to old finished goods from the pandemic period. Management plans to address operational challenges through restructuring and land sale proceeds, while seeking government subsidies under the Compound Semiconductor Scheme.

26 minutes ago

Vistar Amar Limited Reports Strong Q1 Profit Turnaround and Board Changes

sentiment_img

Vistar Amar Limited reported a profit of ₹103.13 lacs for the quarter ended June 30, 2025, compared to a loss of ₹0.21 lacs in the same quarter last year. Revenue from operations increased significantly to ₹2,733.22 lacs from ₹1,141.30 lacs year-over-year. The company's Board approved these unaudited quarterly results and recommended the re-appointment of Mr. Ramesh Ishwarlal Upadhyay as Non-Executive Non-Independent Director, who retires by rotation. The Board also recommended appointing Ms. Chandni Gopal Khudai as Non-Executive Independent Director for a five-year term from October 1, 2025 to September 30, 2030. Additionally, the Board approved remuneration for statutory auditors S A R A & Associates for FY 2025-2026. The company's 41st Annual General Meeting is scheduled for September 16, 2025.

28 minutes ago

INDRAMEDCO Share Price History

View Price History arrow

Close Price

Volume

INDRAMEDCO share price in last 10 trading sessions

DayOpenCloseChange%Day HighDay LowVolume
12 Aug 2025289.00274.90
-4.88% Loss
289.00274.001,20,109
11 Aug 2025275.40276.35
0.34% profit
277.65274.001,11,579
08 Aug 2025284.95274.55
-3.65% Loss
286.55271.351,31,176
07 Aug 2025277.55284.95
2.67% profit
287.20274.251,39,528
06 Aug 2025288.00279.50
-2.95% Loss
290.60276.5078,771
05 Aug 2025297.00287.15
-3.32% Loss
299.45286.2575,247
04 Aug 2025286.05298.00
4.18% profit
301.95284.601,91,485
01 Aug 2025290.00281.25
-3.02% Loss
292.20280.104,95,534
31 Jul 2025284.90288.15
1.14% profit
294.70282.401,16,073
30 Jul 2025295.00290.35
-1.58% Loss
295.60287.6570,670

INDRAMEDCO Fundamentals

View Fundamentals arrow

Company Valuation

Market Cap (₹ Cr.)

4,288

PE Ratio

25.50

PB Ratio

7.18

Dividend Yield

0.96%

ROE

25.95%

ROCE

30.51%

Book Value (₹)

65.09

Face Value (₹)

10.00


Share Holding Pattern

Held ByJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Promoters
51.00%51.00%51.00%51.00%51.00%
Domestic Institutional Investors (DII)
3.15%3.20%3.19%3.56%3.56%
Foreign Institutional Investors (FII)
1.70%2.64%2.88%2.94%2.72%
Public Investors
30.18%30.11%30.44%29.97%29.87%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government


INDRAMEDCO Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

SIP Logo

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.


INDRAMEDCO Technicals

View Technicals arrow

Moving Averages

PeriodSimpleSignal
5-SMA278.05Bearish
10-SMA283.52Bearish
20-SMA294.34Bearish
50-SMA320.04Bearish
100-SMA312.79Bearish
200-SMA289.54Bearish

Technical Indicators

IndicatorValueAction
RSI(14)34.46Neutral
ATR(14)12.84Volatile
STOCH(9,6)18.93Oversold
STOCH RSI(14)45.58Neutral
MACD(12,26)-1.06Bearish
ADX(14)31.05Strong Trend

Summary of Technical Indicators for INDRAMEDCO


Margin on INDRAMEDCO

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions
Intraday20.00%5.00 X
467.7093.54
MTF50.00%2.00 X
467.70233.85
Delivery100.00%1.00 X
467.70467.70

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions.Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).


INDRAMEDCO Financials Summary
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
353356330340372

INDRAMEDCO Financials

Income Statement

In Crores

Quarterly StatementJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Revenue353356330340372
Expenses281286273272292
Operating Profit6764526173
Operating Profit Margin %19%18%16%18%20%
Other Income56567
EBITDA7270576880
Interest22222
Depreciation1111111110
Profit Before Tax6057455568
Tax %0%0%0%0%0%
Net Profit4542334152
EPS55446

Balance Sheet

In Crores

Yearly Balance SheetMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Share Capital9292929292
Reserve & Surplus181234288386505
Non Current Liabilities4343468076
Current Liabilities11694130165179
Total Liabilities432462555723852
Fixed Assets283277275347361
Capital Work in Progress303133
Investments00007
Other Assets1451852783760
Total Assets432462555723852

Cash Flow

In Crores

Yearly Cash FlowMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Operating Activities862794145200
Investing Activities-40-19-74-108-158
Financing Activities-43-3-3-26-32
Net Cash Flow4517119

Corporate Actions

DateCorporate ActionInformation
18th Sept 2025, Thursday
DIVIDENDDividend
Final Dividend of ₹4.5 Per Share
6th Aug 2025, Wednesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 25-26 Results
info
16th May 2025, Friday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 25-26 Results
info
3rd Feb 2025, Monday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q3 FY 24-25 Results
info
30th Oct 2024, Wednesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q2 FY 24-25 Results
info

The above dates are ex-dates.

View All Stock Events arrow

INDRAMEDCO Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2023-241,356
13.29% profit
157
43.89% profit
FY 2022-231,262
23.7% profit
124
46.96% profit
FY 2021-221,109
44.8% profit
86
2415.88% profit

Top Mutual Funds Invested in INDRAMEDCO

logo

Groww Value Fund Direct - Growth

1Y Returns

4.57 %

3Y Returns

17.49 %

5Y Returns

20.83 %







What’s New In The Market
P

PTC India Financial Services Faces Rs 6.4 Lakh Penalty as Regional Director Dismisses Appeals

sentiment_img

PTC India Financial Services Ltd received orders from the Regional Director dismissing all three appeals against Show Cause Notices issued by the Registrar of Companies. The company must pay penalties totaling Rs 6.40 lakh for violations during FY 2021-22. The violations include failing to facilitate Independent Directors in seeking professional legal advice (Rs 70,000 penalty), delays in sharing documents with Independent Directors for legal opinion (Rs 70,000 penalty), and failure to maintain prescribed composition of the Nomination and Remuneration Committee (Rs 5 lakh penalty). The company states there is no material impact on operations except for the penalty amount, for which provisions have already been created in the books of accounts.

20 minutes ago

S

SPEL Semiconductor Announces Leadership Changes and Quarterly Results with Going Concern Qualification

sentiment_img

SPEL Semiconductor Limited's board approved several key decisions on August 13, 2025. The company appointed Dr. G. Nagarajan as Additional Director while Dr. Enakshi Bhattacharya resigned as Independent Director. The board also approved M/s. S Dhanapal & Associates LLP as Secretarial Auditors for 5 years and authorized the sale of open land in factory premises, both subject to shareholder approval. The company released unaudited financial results for the quarter ended June 30, 2025, which received a qualified review from auditors due to material uncertainty about the company's ability to continue as a going concern, citing losses and negative cash flows. The company operates in integrated circuit manufacturing and assembly, with losses attributed mainly to old finished goods from the pandemic period. Management plans to address operational challenges through restructuring and land sale proceeds, while seeking government subsidies under the Compound Semiconductor Scheme.

27 minutes ago

V

Vistar Amar Limited Reports Strong Q1 Profit Turnaround and Board Changes

sentiment_img

Vistar Amar Limited reported a profit of ₹103.13 lacs for the quarter ended June 30, 2025, compared to a loss of ₹0.21 lacs in the same quarter last year. Revenue from operations increased significantly to ₹2,733.22 lacs from ₹1,141.30 lacs year-over-year. The company's Board approved these unaudited quarterly results and recommended the re-appointment of Mr. Ramesh Ishwarlal Upadhyay as Non-Executive Non-Independent Director, who retires by rotation. The Board also recommended appointing Ms. Chandni Gopal Khudai as Non-Executive Independent Director for a five-year term from October 1, 2025 to September 30, 2030. Additionally, the Board approved remuneration for statutory auditors S A R A & Associates for FY 2025-2026. The company's 41st Annual General Meeting is scheduled for September 16, 2025.

28 minutes ago

FAQs

Indraprastha Medical Corporation share price as of today is ₹ 467.70 as on 13 Aug 2025 at 15:57.
The 52W high of Indraprastha Medical Corporation is ₹ 572.00 and 52W low is ₹ 307.25 as of 13 Aug 2025 at 15:57.
The past returns of Indraprastha Medical Corporation share are -
  • Past 1 year: 47.84%
  • Past 3 years: 620.09%
  • Past 5 years: 744.99%
The PE and PB ratio of Indraprastha Medical Corporation stands at 25.50 and 7.18 respectively as on 13 Aug 2025 at 15:57.
The EPS of Indraprastha Medical Corporation is 0.00 for the quarter ended 0.00 and 0.00 for the financial year 0.00.
The shareholding pattern of Indraprastha Medical Corporation is as follows:
  • DIIs - 3.56%
  • FII - 2.72%
  • Promoters - 51.00%
  • Public Investors 29.87%
  • Goverenment - 0.00%
Yes, you can buy shares of Indraprastha Medical Corporation online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Indraprastha Medical Corporation stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Indraprastha Medical Corporation share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Indraprastha Medical Corporation.
You can easily buy the shares of Indraprastha Medical Corporation even after the markets are closed using the After Market Order feature on Dhan Trading App.
Candle bars with Screen
Invest in INDRAMEDCO
Candle bars with Screen

Pay Zero Brokerage on Delivery

Candle bars with Screen

Open FREE Demat Account

Indian Flag

+91

Or Scan the QR Code to download the Dhan App

QR code Logo


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104
Corporate Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India. Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors